Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C

doi:10.3748/wjg.v23.i21.3815

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 21

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9139)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

607

WORD

331

HTML

3430

Tables (1-5)

167

Sum=4535

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1639

Download

2965

Sum=4604

Jun 7, 2017 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Jun 7, 2017; 23(21): 3815-3824
Published online Jun 7, 2017. doi: 10.3748/wjg.v23.i21.3815

Table 1 Frequencies of alleles and genotypes of analyzed IFNL3 (IL28B) single nucleotide polymorphism in the group of patients enrolled (n = 196) n (%)

SNP	Allele frequency	Genotype frequency
rs4803217 (C/A)	C: 215 (54.85)	CC: 54 (27.55)
	A: 177 (45.15)¹	CA: 107 (54.59)
		AA: 35 (17.86)
rs12979860 (C/T)	C: 212 (54.08)	CC: 53 (27.04)
	T: 180 (45.92)¹	CT: 106 (54.08)
		TT: 37 (18.88)
rs8099917 (T/G)	T: 252 (64.29)	TT: 75 (38.27)
	G: 140 (35.71)¹	TG: 102 (52.04)
		GG: 19 (9.69)
rs12980275 (A/G)	A: 227 (57.91)	AA: 64 (32.65)
	G: 165 (42.09)¹	AG: 99 (50.51)
		GG: 33 (16.84)

¹MAF (minor allele frequency). SNP: Single nucleotide polymorphism.

Table 2 Association between IFNL3 (IL28B) single nucleotide polymorphism and sustained virological response after pegylated interferon alpha and ribavirin treatment in chronic hepatitis C patients

SNP	Allele/genotype	Response (n = 54), n (%)	Non-response (n = 126), n (%)	Response vs non-response	OR_crude (95%CI)/OR_adjusted (95%CI)¹	P_crude/P_adjusted¹
rs4803217 (C/A)	C/A	85 (78.70)/23 (21.30)	109 (43.25)/143 (56.75)	C/A	4.848 (2.871-8.186)	< 0.0001^a
	CC	34 (62.96)	14 (11.11)	CC/CA + AA	13.6 (6.219-29.770)/8.357 (3.013-23.181)	< 0.0001^a/< 0.0001^a
	CA	17 (31.48)	81 (64.29)	CC + CA/AA	5.547 (1.617-19.035)/3.240 (0.849-12.367)	0.003^a/0.082
	AA	3 (55.56)	31 (24.60)	Dose of C allele	7.588 (3.858-14.922)/4.310 (1.956-9.500)	< 0.0001^a/0.0002^a
rs12979860 (C/T)	C/T	82 (75.93)/26 (24.07)	108 (42.86)/144 (57.14)	C/T	4.205 (2.533-6.980)	< 0.0001^a
	CC	32 (59.26)	14 (11.11)	CC/CT + TT	11.636 (5.351-25.306)/9.765 (3.407-27.990)	< 0.0001^a/< 0.0001^a
	CT	18 (33.33)	80 (63.49)	CC + CT/TT	4.255 (1.424-12.715)/4.413 (0.927-21.011)	0.006^a/0.059
	TT	4 (7.41)	32 (25.40)	Dose of C allele	6.072 (3.195-11.538)/5.574 (2.345-13.246)	< 0.0001^a/< 0.0001^a
rs8099917 (T/G)	T/G	80 (74.07)/28 (25.93)	149 (59.13)/103 (40.87)	T/G	1.975 (1.2-3.251)	0.007^a
	TT	29 (53.70)	39 (30.95)	TT/TG + GG	2.588 (1.344-4.981)/2.097 (0.844-5.210)	0.004^a/0.107
	TG	22 (40.74)	71 (56.35)	TT + TG/GG	2.473 (0.690-8.867)/2.397 (0.482-11.926)	0.153/0.280
	GG	3 (5.56)	16 (12.70)	Dose of T allele	2.190 (1.266-3.788)/1.869 (0.911-3.837)	0.0048^a/0.0845
rs12980275 (A/G)	A/G	85 (78.70)/23 (21.30)	120 (47.62)/132 (52.38)	A/G	4.065 (2.410-6.857)	< 0.0001^a
	AA	35 (64.81)	23 (18.25)	AA/AG + GG	8.249 (4.021-16.923)/5.225 (1.999-13.658)	< 0.0001^a/0.001^a
	AG	15 (27.78)	74 (58.73)	AA + AG/GG	3.737 (1.244-11.223)/4.075 (0.848-19.589)	0.013^a/0.076
	GG	4 (7.41)	29 (23.02)	Dose of A allele	4.705 (2.591-8.542)/3.596 (1.659-7.791)	< 0.0001^a/0.001^a

¹Adjusted for staging;

^aP < 0.05. SNP: Single nucleotide polymorphism.

Table 3 Multivariate analysis of factors associated with outcome of chronic hepatitis C treatment with pegylated interferon alpha and ribavirin

Variable	OR (95%CI)	P value
Response (SVR)¹
rs4803217 (C/A)	4.979 (1.344-18.444)	0.016^a
rs12979860 (C/T)	1.499 (0.446-5.042)	0.510
rs8099917 (T/G)	0.594 (0.247-1.429)	0.242
rs12980275 (A/G)	1.658 (0.598-4.594)	0.328
Stage of fibrosis	3.278 (1.108-9.698)	0.031^a
Relapse²
rs4803217 (C/A)	0.134 (0.023-0.789)	0.024^a
rs12979860 (C/T)	2.381 (0.444-12.773)	0.303
rs12980275 (A/G)	1.046 (0.369-2.961)	0.932

¹Model summary: χ² (5) = 56.028; P < 0.0001, constant: < 0.0001. rs4803217, rs12979860, rs8099917, rs12980275 (dose allele model) an stage of fibrosis were included in the analysis;

²Model summary: χ² (3) = 12.337, P < 0.00632, constant: P = 0.019. rs4803217, rs12979860, and rs12980275 (dose allele model) were included in the analysis.

^aP < 0.05 (independent factors). SVR: Sustained virological response.

Table 4 Association of IFNL3 (IL28B) rs4803217 and rs8099917 combined genotypes with response to pegylated interferon alpha and ribavirin treatment

Genotypes/combined genotypes	SVR (n = 54), n	Non-response (n = 126), n	OR (95%CI)	P value
rs4803217CC/rs8099917TT	22	13	0.697 (0.276-1.759)	0.442
rs4803217CC/rs8099917TG	12	1	4.941 (0.586-41.699)	0.156
rs4803217CC¹	34	14	Ref.	-
rs4803217CA/rs8099917TT	5	9	2.813 (0.832-9.504)	0.136
rs4803217CA/rs8099917TG	9	71	0.641 (0.267-1.542)	0.388
rs4803217CA/rs8099917GG	2	1	10.125 (0.865-118.471)	0.083
rs4803217CA	16	81	Ref.	-
rs4803217AA/rs8099917TT	1	2	5.167 (0.355-75.138)	0.298
rs4803217AA/rs8099917TG	1	14	0.738 (0.070-7.736)	1.000
rs4803217AA/rs8099917GG	1	15	0.689 (0.066-7.192)	1.000
rs4803217AA	3	31	Ref.	-

¹Combination of rs4803217CC and rs8099917GG genotypes was not observed. SNP: Single nucleotide polymorphism; SVR: Sustained virological response.

Table 5 Association between IFNL3 (IL28B) gene single nucleotide polymorphism and relapse after pegylated interferon alpha and ribavirin treatment in chronic hepatitis C patients

SNP	Allele/genotype	Relapse (n = 39), n (%)	Non-relapse (n = 38), n (%)	Relapse vs non-relapse	OR (95%CI)	P value
rs4803217 (C/A)	C/A	38 (48.72)/40 (51.28)	56 (73.68)/20 (26.32)	C vs A	0.339 (0.173-0.667)	0.001^a
	CC	7 (17.95)	21 (55.26)	CC vs CA + AA	0.177 (0.063-0.500)	0.0007^a
	CA	24 (61.54)	14 (36.84)	CC + CA vs AA	0.332 (0.081-1.364)	0.113
	TT	8 (20.51)	3 (7.89)	Dose of C allele	0.296 (0.134-0.653)	0.002^a
rs12979860 (C/T)	C/T	40 (51.28)/38 (48.72)	52 (68.42)/24 (31.58)	C vs T	0.486 (0.252-0.937)	0.030^a
	CC	8 (20.51)	18 (47.37)	CC vs CT + TT	0.287 (0.105-0.783)	0.013^a
	CT	24 (61.54)	16 (42.11)	CC + CT vs TT	0.538 (0.143-2.013)	0.351
	TT	7 (17.95)	4 (10.53)	Dose of C allele	0.442 (0.211-0.925)	0.028^a
rs8099917 (T/G)	T/G	56 (71.79)/22 (28.21)	52 (68.42)/24 (31.58)	T vs G	1.175 (0.589-2.344)	0.647
	TT	21 (53.85)	17 (44.74)	TT vs TG + GG	1.304 (0.526-3.233)	0.566
	TG	14 (35.90)	18 (47.37)	TT + TG vs GG	0.750 (0.156-3.560)	1.000
	GG	4 (10.26)	3 (7.89)	Dose of T allele	1.174 (0.582-2.365)	0.649
rs12980275 (A/G)	A/G	45 (57.69)/33 (42.31)	56 (73.68)/20 (26.32)	A vs G	0.487 (0.247-0.961)	0.037^a
	AA	12 (30.77)	22 (57.89)	AA vs AG + GG	0.323 (0.127-0.825)	0.017^a
	AG	21 (53.85)	12 (31.58)	AA + AG vs GG	0.647 (0.167-2.503)	0.737
	GG	6 (15.38)	4 (10.53)	Dose of A allele	0.495 (0.245-0.998)	0.046^a

^aP < 0.05. SVR: Sustained virological response.

Citation: Świątek-Kościelna B, Kałużna E, Strauss E, Nowak J, Bereszyńska I, Gowin E, Wysocki J, Rembowska J, Barcińska D, Mozer-Lisewska I, Januszkiewicz-Lewandowska D. Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C. World J Gastroenterol 2017; 23(21): 3815-3824
URL: https://www.wjgnet.com/1007-9327/full/v23/i21/3815.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i21.3815